Retatrutide vs Semaglutide
Both are weekly injections. Both target obesity. But the science, the results, and the mechanism are in a completely different league. Here is an honest, data-driven comparison of the two most-discussed weight-loss drugs available in Thailand today.
How They Work Differently
The mechanism gap explains the results gap
Suppresses appetite, slows gastric emptying, triggers satiety signals in the brain
Enhances insulin response, improves glucose disposal, synergises with GLP-1 for amplified appetite control
Activates lipolysis (fat breakdown), raises resting energy expenditure, directly reduces liver fat — not available in any other approved obesity drug
Suppresses appetite, slows gastric emptying, triggers satiety signals — the same as Retatrutide’s first lever
Not targeted by Semaglutide — this pathway remains unused
Not targeted — no fat-burning acceleration or increased energy expenditure
Full Side-by-Side Comparison
Every major factor, objectively compared
| Factor | Retatrutide | Semaglutide |
|---|---|---|
| Drug Class | Triple Agonist (GLP-1 + GIP + Glucagon) | Single Agonist (GLP-1 only) |
| Average Weight Loss | ~24% of body weight | 10–15% of body weight |
| Patients Losing ≥15% | 83% of patients | ~37% of patients |
| Injection Frequency | Once weekly | Once weekly |
| Time to First Results | 3–4 weeks | 6–12 weeks |
| Liver Fat Reduction | 57–80% reduction | Moderate reduction |
| Effect on Metabolism | Raises resting energy expenditure | Minimal effect on metabolism |
| Fat Burning (Lipolysis) | Direct activation via glucagon | Indirect (calorie deficit only) |
| Blood Sugar Control | Excellent (3-pathway approach) | Good (GLP-1 pathway) |
| Regulatory Status | Phase 3 trials (pre-approval) | FDA/EMA approved |
| Available in Thailand | Yes — now available | Limited availability |
| Nausea Profile | Mild–moderate (weeks 1–3) | Mild–moderate (weeks 1–4) |
| Oral Option | Injection only | Yes (Rybelsus oral tablet) |
| Long-term Safety Data | 2+ years trial data | 6+ years post-market data |
The Weight Loss Results Gap
Visualising what the clinical data actually means for your body
Which Is Right for You?
An honest guide — not every patient is the same
Consider Retatrutide if…
You want maximum results and access to the most advanced treatment
- You have significant weight to lose (BMI 35+) and want the most effective option
- You have tried Semaglutide and found results insufficient
- You have non-alcoholic fatty liver disease (NAFLD) — Retatrutide’s liver fat reduction is far superior
- You want faster results — appetite suppression often begins within days
- You have metabolic syndrome or elevated triglycerides that need addressing alongside weight
- You are already in Thailand or willing to travel for treatment access
Consider Semaglutide if…
Regulatory approval and established track record matter most to you
- You prefer an FDA-approved medication with a multi-year post-market safety record
- Your target weight loss is moderate (10–15%) and Semaglutide’s profile is sufficient
- You have insurance coverage for Wegovy or Ozempic in your home country
- You cannot tolerate injections and want the oral Rybelsus option
- You are new to GLP-1 therapy and want to start with the most studied drug in the class
Many patients transition to Retatrutide after plateauing on Semaglutide. Because Retatrutide activates GIP and Glucagon in addition to GLP-1, it provides meaningful additional benefit even in patients already familiar with the GLP-1 class. Our team has experience managing this transition safely.
Side Effects: How They Compare
Both drugs share a similar GI side effect profile — here is what to expect from each
Shared Side Effects
Because both activate GLP-1, they produce similar gastrointestinal effects, especially early in treatment.
- Mild Nausea (most common, usually weeks 1–3)
- Mild Reduced appetite beyond the intended effect
- Mild Constipation or loose stools
- Mild Injection site irritation
- Mild Fatigue during initial dose adjustment
💡 Most GI effects are transient — they peak early and subside significantly by week 4.
Retatrutide-Specific Considerations
The glucagon component adds unique considerations not seen with Semaglutide alone.
- Note Slightly elevated heart rate in some patients (glucagon effect)
- Note Greater initial nausea intensity at higher doses (managed with slow titration)
- Note More pronounced appetite suppression — eating schedule adjustments required
- Benefit Superior liver fat reduction vs Semaglutide
- Benefit Greater improvement in triglycerides and metabolic markers
All side effects are managed with our “Start Low, Go Slow” dosing protocol and weekly check-ins.
Common Questions: Retatrutide vs Semaglutide
The questions we hear most from patients comparing the two
Can I switch from Semaglutide to Retatrutide?
+Yes, and it is a transition our team manages regularly. Because both drugs activate the GLP-1 receptor, patients moving from Semaglutide to Retatrutide typically experience a smoother adjustment than first-time users. We begin at a low Retatrutide dose regardless of previous Semaglutide dose to ensure tolerance to the additional GIP and Glucagon activity. Most transitioning patients notice a meaningful improvement in weight loss progress within 4–6 weeks.
Is Retatrutide more expensive than Semaglutide?
+In Thailand, Retatrutide is competitively priced and in many cases comparable to Semaglutide sourced through the same channels. Branded Semaglutide (Wegovy) in Western markets carries a significant premium and limited insurance coverage. We recommend contacting us directly for current pricing, as it can vary based on dose and supply. Payment plans are available to make treatment accessible.
Is Retatrutide safe if Semaglutide caused me side effects?
+This depends on what side effects you experienced. If your Semaglutide side effects were GI-related (nausea, constipation), Retatrutide may produce similar initial effects — but our slow titration protocol is specifically designed to minimise this. If you discontinued Semaglutide for a more serious reason (e.g. pancreatitis risk, thyroid concerns), a thorough medical assessment is essential before starting Retatrutide. Please share your full history during the consultation.
Why choose Retatrutide when Semaglutide is already FDA approved?
+FDA approval reflects a regulatory process — not necessarily the best therapeutic outcome. Retatrutide’s Phase 2 data is published in the New England Journal of Medicine, one of the most rigorous peer-reviewed journals in medicine. Many of the world’s most effective treatments are used in supervised clinical or prescription settings before full approval. The key question is: which drug is more likely to help you reach your goal? For most patients seeking maximum weight loss, the data strongly favours Retatrutide.
Does Retatrutide work if I have type 2 diabetes, like Ozempic does?
+Yes — and potentially more effectively. Retatrutide’s triple-receptor approach provides superior glucose regulation compared to GLP-1 monotherapy. Its GIP activation enhances insulin secretion and sensitivity, while the GLP-1 component reduces post-meal glucose spikes. Patients with type 2 diabetes will likely need their existing diabetes medications adjusted as their blood sugar improves. This is managed carefully by our medical team throughout treatment.
How much more weight will I lose with Retatrutide versus Semaglutide?
+Based on clinical trial averages, Retatrutide produces approximately 60–70% more weight loss than Semaglutide (24% vs 15% of body weight over 48 weeks). For a 100 kg patient, that is roughly 24 kg vs 15 kg — a difference of about 9 kg at average doses. At the highest Retatrutide doses, some trial participants lost over 30% of body weight. However, individual responses vary significantly based on genetics, metabolism, lifestyle, and adherence.
Not Sure Which Is Right for You?
Our medical team will review your health history, previous treatments, and goals to recommend the right path — with no pressure or obligation.
- + Review of any previous GLP-1 treatment history
- + Full metabolic and health assessment
- + Personalised recommendation: Retatrutide, Semaglutide, or Tirzepatide
- + Transparent discussion of costs and timeline
- + Available in English and Thai
Get Free Recommendation
Confirmation within 24 hours · No obligation